Recent research have centered on the convergence of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|glucagon receptor activator therapies and DA signaling. While GIP activators are widely employed for addressing type 2 diabetes, their emerging effects on reward circuits, spec